Third consensus on medical treatment of metastatic breast cancer
Open Access
- 16 July 2009
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 20 (11) , 1771-1785
Abstract
Background: Treatment options for patients with metastatic breast cancer (MBC) include a rapidly expanding repertoire of medical, surgical and supportive care measures. Design: To provide timely and evidence-based recommendations for the diagnostic workup and treatment of patients with MBC, an international expert panel reviewed and discussed the evidence available from clinical trials regarding diagnostic, therapeutic and supportive measures with emphasis on their impact on the quality of life and overall survival of patients with MBC. Results: Evidence-based recommendations for the diagnostic workup, endocrine therapy, chemotherapy, use of targeted therapies and bisphosphonates, surgical treatment and supportive care measures in the management of patients with MBC were formulated. Conclusions: The present consensus manuscript updates evidence-based recommendations for state-of-the-art treatment of MBC depending on disease-associated and biological variables.Keywords
Funding Information
- Bristol Myers-Squibb
- Eli Lilly
- Roche
This publication has 172 references indexed in Scilit:
- Differentiating Proteomic Biomarkers in Breast Cancer by Laser Capture Microdissection and MALDI MSJournal of Proteome Research, 2008
- Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated AnemiaJAMA, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Genomic signatures to guide the use of chemotherapeuticsNature Medicine, 2006
- EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumoursEuropean Journal of Cancer, 2006
- Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effectsAnnals of Oncology, 2005
- Oncogenic pathway signatures in human cancers as a guide to targeted therapiesNature, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Breast cancer and hormone-replacement therapy in the Million Women StudyThe Lancet, 2003
- Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levelsAnnals of Oncology, 2002